Novocure Reports Promising Tumor Treating Fields Therapy Study for Brain Metastases
Thursday, 28 March 2024, 15:50
Key Points:
- Novocure stock surged 6.3% higher today after positive study results on Tumor Treating Fields therapy.
- Patients receiving TTFields therapy had a median time to intracranial progression of 21.9 months, showing significant improvement.
- However, key secondary endpoints like overall survival and neurocognitive failure were not achieved.
Conclusion:
Novocure's stock surge is fueled by promising Tumor Treating Fields therapy results, but challenges remain with unmet study endpoints.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.